Cart
sales@molnova.com
Levalbuterol tartrate
CAS No. 661464-94-4
Levalbuterol tartrate ( Levosalbutamol tartrate )
Catalog No. M15519 CAS No. 661464-94-4
A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 74 | In Stock |
|
| 10MG | 128 | In Stock |
|
| 50MG | 201 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLevalbuterol tartrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
-
DescriptionA short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).Asthma Approved
-
SynonymsLevosalbutamol tartrate
-
PathwayAngiogenesis
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research AreaInflammation/Immunology
-
IndicationAsthma
Chemical Information
-
CAS Number661464-94-4
-
Formula Weight628.71
-
Molecular FormulaC30H48N2O12
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.C(C(C(=O)O)O)(C(=O)O)O
-
Chemical Name1,3-Benzenedimethanol, α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (α1R)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Midodrine
Midodrine is a selective α1-adrenoceptor agonist that acts as a vasopressor/antihypotensive agent for the treatment of dysautonomia and orthostatic hypotension.
-
nifenalol.HCl
Nifenalol is a antagonist of β-adrenergic receptor.
-
Dabuzalgron
Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.
